Signatur Biosciences

Signatur Biosciences is a healthcare company located in London, England, focused on the diagnostics sub-industry. Established in 2022 and part of the Y-Combinator S22 batch, the company has a small team of five members. Signatur Biosciences aims to transform medical diagnostics by making precision diagnostics more accessible, starting with breast cancer prognosis. Their innovative approach allows tests to be easily conducted by local hospital labs, significantly reducing both the cost and turnaround time from over three weeks to just a few days. The company’s technology leverages molecular intelligence applied to widely accessible PCR equipment, simplifying the diagnosis of complex diseases without the need for laborious tests and expensive machines. Currently, they are expanding their PCR testing capabilities to cover a broader range of conditions. The founders of Signatur Biosciences include Dr. John Goertz and Celestin de Wergifosse, with Prof. Molly Stevens serving as a Non-Executive Director. The company serves various regions including the United Kingdom and Europe, and offers both remote and partly remote services.